Expanded Use of Glivec Approved by EU: Novartis

by Kathy Jones on  February 28, 2012 at 7:46 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The European Union will allow an expanded use of the drug Glivec to treat certain rare forms of gastrointestinal cancer, Novartis has revealed.
 Expanded Use of Glivec Approved by EU: Novartis
Expanded Use of Glivec Approved by EU: Novartis

The European Commission approved an update to the Glivec label to include 36 months of treatment after surgery "for adults with KIT (CD117)-positive gastrointestinal stromal tumors (GIST)," Novartis said in a statement.

"Gastrointestinal stromal tumors are a rare, life-threatening cancer of the gastrointestinal tract," it said.

They are often difficult to diagnose and treat because they may not cause physical symptoms.

The cancers are usually diagnosed in patients aged between 55 and 65, and are characterised by tumors of connective tissue supporting the digestive tract.

Last year Novartis said sales of Glivec reached $4.7 billion (3.5 billion euros).

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive